This expansion announcement came right after raising series B funding of $27 Mn in a round led by Fundamentum Partnership, earlier this month.
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Subscribe To Our Newsletter & Stay Updated
